Ptc Therapeutics Financials
This page shows Ptc Therapeutics (PTCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 profit surge came from a high-margin revenue step-up, not from shrinking R&D or a capital-heavy model.
The latest year’s revenue more than doubled to$1.73B while combined R&D and SG&A stayed near$800M , so the move into profit reflects a high-margin revenue shift rather than a stripped-down operating model. The preceding stretch showed persistent losses despite heavy R&D, so this looks less like gradual cost leverage and more like a step-change in what each extra dollar of revenue was worth.
Cash followed accounting profit closely: operating cash flow was
The balance sheet still carries the weight of earlier losses: equity remained
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ptc Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ptc Therapeutics has an operating margin of 50.1%, meaning the company retains $50 of operating profit per $100 of revenue. This results in a moderate score of 45/100, indicating healthy but not exceptional operating efficiency. This is up from -37.5% the prior year.
Ptc Therapeutics's revenue surged 114.5% year-over-year to $1.7B, reflecting rapid business expansion. This strong growth earns a score of 91/100.
Ptc Therapeutics has a moderate D/E ratio of -15.12. This balance of debt and equity financing earns a leverage score of 31/100.
With a current ratio of 2.35, Ptc Therapeutics holds $2.35 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 66/100.
Ptc Therapeutics converts 40.6% of revenue into free cash flow ($702.3M). This strong cash generation earns a score of 73/100.
Ptc Therapeutics scores 2.13, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($7.4B) relative to total liabilities ($3.1B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ptc Therapeutics passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Ptc Therapeutics generates $1.04 in operating cash flow ($711.2M OCF vs $683.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Ptc Therapeutics generated $1.7B in revenue in fiscal year 2025. This represents an increase of 114.5% from the prior year.
Ptc Therapeutics's EBITDA was $905.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 499.2% from the prior year.
Ptc Therapeutics reported $683.0M in net income in fiscal year 2025. This represents an increase of 288.0% from the prior year.
Ptc Therapeutics earned $7.78 per diluted share (EPS) in fiscal year 2025. This represents an increase of 264.5% from the prior year.
Cash & Balance Sheet
Ptc Therapeutics generated $702.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 715.1% from the prior year.
Ptc Therapeutics held $984.6M in cash against $0 in long-term debt as of fiscal year 2025.
Ptc Therapeutics had 81M shares outstanding in fiscal year 2025. This represents an increase of 4.9% from the prior year.
Margins & Returns
Ptc Therapeutics's operating margin was 50.1% in fiscal year 2025, reflecting core business profitability. This is up 87.6 percentage points from the prior year.
Ptc Therapeutics's net profit margin was 39.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 84.5 percentage points from the prior year.
Capital Allocation
Ptc Therapeutics invested $455.2M in research and development in fiscal year 2025. This represents a decrease of 14.8% from the prior year.
Ptc Therapeutics invested $8.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 36.3% from the prior year.
PTCT Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $272.6M+65.5% | $164.7M-22.0% | $211.0M+18.0% | $178.9M-84.8% | $1.2B+451.7% | $213.2M+8.3% | $196.8M+5.4% | $186.7M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $100.9M-24.2% | $133.1M+32.9% | $100.2M-11.4% | $113.0M+3.7% | $109.0M-12.7% | $124.8M-22.7% | $161.4M+22.1% | $132.2M |
| SG&A Expenses | $86.2M-11.0% | $96.9M+15.3% | $84.0M-1.4% | $85.3M+5.3% | $81.0M-4.4% | $84.7M+15.3% | $73.5M+5.7% | $69.5M |
| Operating Income | $45.0M+163.0% | -$71.3M-2465.7% | $3.0M+108.6% | -$35.0M-103.6% | $970.2M+697.5% | -$162.4M-197.9% | -$54.5M-35.5% | -$40.2M |
| Interest Expense | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $347K+108.4% | -$4.1M+89.4% | -$39.0M-528.2% | -$6.2M-109.8% | $63.3M+319.6% | -$28.8M-432.6% | $8.7M-35.6% | $13.4M |
| Net Income | -$2.8M+97.9% | -$134.6M-946.8% | $15.9M+124.5% | -$64.8M-107.5% | $866.6M+1415.1% | -$65.9M+38.2% | -$106.7M-7.5% | -$99.2M |
| EPS (Diluted) | $-0.03 | N/A | $0.20+124.1% | $-0.83-108.3% | $10.04 | N/A | $-1.39-7.8% | $-1.29 |
PTCT Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.9B-1.0% | $2.9B+9.6% | $2.6B+0.4% | $2.6B-0.8% | $2.7B+55.7% | $1.7B-7.4% | $1.8B-3.9% | $1.9B |
| Current Assets | $2.3B-0.9% | $2.3B+13.3% | $2.0B-11.7% | $2.3B-1.9% | $2.3B+69.6% | $1.4B+6.6% | $1.3B-5.6% | $1.4B |
| Cash & Equivalents | $834.0M-15.3% | $984.6M+46.4% | $672.6M-33.9% | $1.0B-31.3% | $1.5B+89.8% | $779.7M+48.2% | $526.0M-19.7% | $654.8M |
| Inventory | $75.6M-5.1% | $79.6M+51.2% | $52.7M+54.7% | $34.1M+57.1% | $21.7M-6.5% | $23.2M-35.0% | $35.7M+12.1% | $31.8M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M0.0% | $82.3M |
| Total Liabilities | $3.0B-1.8% | $3.1B+10.9% | $2.8B-1.5% | $2.8B0.0% | $2.8B+1.4% | $2.8B-3.2% | $2.9B0.0% | $2.9B |
| Current Liabilities | $923.6M-4.6% | $968.4M+11.8% | $866.2M+38.0% | $627.8M+5.4% | $595.4M+2.5% | $581.0M-4.9% | $610.7M+0.1% | $609.8M |
| Long-Term Debt | $286.9M | N/A | N/A | $286.0M+0.1% | $285.7M+0.1% | $285.4M+0.1% | $285.1M+0.1% | $284.8M |
| Total Equity | -$180.5M+12.1% | -$205.3M-31.8% | -$155.8M+24.6% | -$206.5M-11.2% | -$185.8M+83.1% | -$1.1B-4.1% | -$1.1B-7.6% | -$980.2M |
| Retained Earnings | -$3.0B-0.1% | -$3.0B-4.8% | -$2.8B+0.6% | -$2.8B-2.3% | -$2.8B+23.8% | -$3.6B-1.8% | -$3.6B-3.1% | -$3.5B |
PTCT Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$59.0M-72.3% | -$34.3M+48.3% | -$66.3M-13.7% | -$58.3M-106.7% | $870.1M+3000.0% | -$30.0M+61.0% | -$77.0M-7.8% | -$71.5M |
| Capital Expenditures | $1.2M-49.6% | $2.4M-31.1% | $3.4M+161.6% | $1.3M-23.6% | $1.7M-54.2% | $3.8M+621.6% | $522K+107.1% | -$7.4M |
| Free Cash Flow | -$60.2M-64.4% | -$36.6M+47.5% | -$69.7M-16.9% | -$59.6M-106.9% | $868.4M+2671.4% | -$33.8M+56.4% | -$77.5M+1.7% | -$78.8M |
| Investing Cash Flow | -$93.7M-375.6% | $34.0M+111.7% | -$289.6M+31.4% | -$422.0M-128.9% | -$184.4M-168.9% | $267.7M+727.3% | -$42.7M+35.3% | -$65.9M |
| Financing Cash Flow | $6.4M-97.9% | $302.5M+1887.7% | $15.2M+284.2% | $4.0M-57.9% | $9.4M-64.5% | $26.5M+250.2% | -$17.6M-107.2% | $246.5M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PTCT Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 16.5%+59.8pp | -43.3%-44.8pp | 1.4%+21.0pp | -19.5%-102.0pp | 82.5%+158.7pp | -76.2%-48.5pp | -27.7%-6.2pp | -21.5% |
| Net Margin | -1.0%+80.7pp | -81.7%-89.3pp | 7.5%+43.8pp | -36.3%-109.9pp | 73.7%+104.6pp | -30.9%+23.3pp | -54.2%-1.1pp | -53.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -0.1%+4.5pp | -4.6%-5.2pp | 0.6%+3.1pp | -2.5%-35.1pp | 32.6%+36.5pp | -3.9%+1.9pp | -5.8%-0.6pp | -5.2% |
| Current Ratio | 2.44+0.1 | 2.35+0.0 | 2.32-1.3 | 3.62-0.3 | 3.89+1.5 | 2.35+0.3 | 2.10-0.1 | 2.23 |
| Debt-to-Equity | -16.90-1.8 | -15.12+2.9 | -17.97-16.6 | -1.38+0.2 | -1.54-1.3 | -0.26+0.0 | -0.27+0.0 | -0.29 |
| FCF Margin | -22.1%+0.2pp | -22.3%+10.8pp | -33.1%+0.3pp | -33.4%-107.2pp | 73.8%+89.7pp | -15.8%+23.5pp | -39.4%+2.8pp | -42.2% |
Note: Shareholder equity is negative (-$205.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Ptc Therapeutics's annual revenue?
Ptc Therapeutics (PTCT) reported $1.7B in total revenue for fiscal year 2025. This represents a 114.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ptc Therapeutics's revenue growing?
Ptc Therapeutics (PTCT) revenue grew by 114.5% year-over-year, from $806.8M to $1.7B in fiscal year 2025.
Is Ptc Therapeutics profitable?
Yes, Ptc Therapeutics (PTCT) reported a net income of $683.0M in fiscal year 2025, with a net profit margin of 39.5%.
What is Ptc Therapeutics's EBITDA?
Ptc Therapeutics (PTCT) had EBITDA of $905.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ptc Therapeutics's operating margin?
Ptc Therapeutics (PTCT) had an operating margin of 50.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Ptc Therapeutics's net profit margin?
Ptc Therapeutics (PTCT) had a net profit margin of 39.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Ptc Therapeutics's free cash flow?
Ptc Therapeutics (PTCT) generated $702.3M in free cash flow during fiscal year 2025. This represents a 715.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ptc Therapeutics's operating cash flow?
Ptc Therapeutics (PTCT) generated $711.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Ptc Therapeutics's total assets?
Ptc Therapeutics (PTCT) had $2.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Ptc Therapeutics's capital expenditures?
Ptc Therapeutics (PTCT) invested $8.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Ptc Therapeutics spend on research and development?
Ptc Therapeutics (PTCT) invested $455.2M in research and development during fiscal year 2025.
What is Ptc Therapeutics's current ratio?
Ptc Therapeutics (PTCT) had a current ratio of 2.35 as of fiscal year 2025, which is generally considered healthy.
What is Ptc Therapeutics's debt-to-equity ratio?
Ptc Therapeutics (PTCT) had a debt-to-equity ratio of -15.12 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ptc Therapeutics's return on assets (ROA)?
Ptc Therapeutics (PTCT) had a return on assets of 23.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is Ptc Therapeutics's debt-to-equity ratio negative or unusual?
Ptc Therapeutics (PTCT) has negative shareholder equity of -$205.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Ptc Therapeutics's Altman Z-Score?
Ptc Therapeutics (PTCT) has an Altman Z-Score of 2.13, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ptc Therapeutics's Piotroski F-Score?
Ptc Therapeutics (PTCT) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ptc Therapeutics's earnings high quality?
Ptc Therapeutics (PTCT) has an earnings quality ratio of 1.04x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ptc Therapeutics?
Ptc Therapeutics (PTCT) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.